Want to join the conversation?
In 2Q16, net sales for $MNK's Acthar were up nearly 9% driven primarily by steady volume growth. INOMAX net sales were up 14% on a pro forma basis. The Therakos platform had net sales growth of 13% on a pro forma basis, on a constant currency basis. In the surgical space, $MNK achieved 4% revenue growth for OFIRMEV.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?